[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"dry-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:dry-age-related-macular-degeneration":60},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,80,112,137,158,183,201,223,252,273,295,317],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100054204","evaluation-of-an-electric-stimulator-for-medical-use-by-personal-lrtpm1-for-visual-function-in-early-to-intermediate-dry-age-related-macular-degeneration-100054204",false,"NCT07700147","Evaluation of an Electric Stimulator for Medical Use by Personal (LRTPM1) for Visual Function in Early to Intermediate Dry Age-Related Macular Degeneration","A Multicenter, Randomized, Double-Blind, Sham-Controlled, Parallel-Group Exploratory Clinical Trial Evaluating the Efficacy and Safety of an Electric Stimulator for Medical Use by Personal (LRTPM1) in Improving Visual Function in Patients With Early to Intermediate Dry Age-Related Macular Degeneration","Inclusion Criteria:\n\n1. Participants aged 50 years or older\n2. Participants diagnosed with early or intermediate dry age-related macular degeneration\n3. Participants with best corrected visual acuity measured by the ETDRS visual acuity chart of 20\u002F200 or better and 20\u002F30 or worse\n4. Participants who have voluntarily decided to participate in the study and have provided written informed consent.\n\nExclusion Criteria:\n\n1. Participants with atrophy involving the foveal center with a diameter of 175 micrometers or greater in at least one eye, as observed by fundus examination or fundus autofluorescence imaging\n2. Participants with exudative age-related macular degeneration in at least one eye, as observed by fundus examination or optical coherence tomography (OCT)\n3. Participants with a history of intraocular injection therapy or macular laser treatment, including focal laser photocoagulation or photodynamic therapy\n4. Participants with retinal or choroidal diseases other than early or intermediate age-related macular degeneration that may affect the study results, including diabetic retinopathy, retinal artery occlusion, retinal vein occlusion, central serous chorioretinopathy, optic neuritis, or uveitis\n5. Participants who have undergone vitrectomy due to retinal disease, or cataract surgery within 1 month prior to screening\n6. Participants with ocular media opacity or other conditions that, in the investigator's opinion, may make ophthalmic imaging difficult to interpret, including cataract, vitreous opacity, or vitreous hemorrhage\n7. Participants with uncontrolled chronic systemic diseases, including diabetes mellitus or chronic kidney disease, or a history of malignancy, except for cases with no recurrence within the past 5 years and no history of chemotherapy\n8. Participants with autoimmune diseases, including Sjögren's syndrome, rheumatoid arthritis, systemic lupus erythematosus, or Graves' disease\n9. Participants with severe hearing impairment, sensory abnormalities, or cognitive impairment that may make it difficult to properly perform the study procedures or recognize or report adverse events\n10. Participants who are hypersensitive to orbital nerve stimulation and are unable to receive treatment\n11. Participants with a history of drug or alcohol abuse\n12. Participants diagnosed with psychiatric disorders, including depression, schizophrenia, bipolar disorder, or dementia\n13. Participants who have participated in another clinical trial within 30 days prior to screening\n14. Participants who are considered to have other contraindications to use of the investigational medical device, including underlying cardiac disease, seizure-related disorders, implanted metal or electronic devices in the head or neck area including deep brain stimulators, unexplained pain, implanted or wearable pacemakers, or other conditions listed in the product precautions and contraindications. Dental implants are exempt.\n15. Participants who, in the opinion of the investigator, are deemed inappropriate for participation in the study\n16. Female participants of childbearing potential who do not agree to use medically accepted contraception during the study period. Medically accepted methods of contraception include condoms, oral contraceptives used consistently for at least 3 months, injectable or implantable contraceptives, or intrauterine devices.","ALL","50 Years",{"count":19,"type":20},40,"ESTIMATED","INTERVENTIONAL",[23],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of an electric stimulator for medical use by personal (LRTPM1) in patients with early to intermediate dry age-related macular degeneration.\n\nThe main questions this study aims to answer are:\n\n* Does the investigational device improve visual function, as assessed by best corrected visual acuity and contrast sensitivity?\n* What treatment-emergent adverse events occur during the study?\n\nParticipants will:\n\n* Be randomized to receive either active stimulation or sham stimulation\n* Apply the assigned investigational device at home once daily for 30 minutes over a 12-week treatment period\n* Visit the study site for eye examinations and safety assessments\n* Return for a follow-up visit 4 weeks after the end of treatment",[26,27],"Dry Age-Related Macular Degeneration","AMD",[29,30,31,32],"Neurostimulation","Electrical stimulation","ES","stimulation","NOT_YET_RECRUITING","2026-07-07",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":20},"2026-07-09",{"date":41,"type":20},"2028-04-17",{"name":43,"class":44},"Nu Eyne Co., Ltd.","INDUSTRY",3,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100645379","cirrus-2023-1-clinical-clin-assessment-of-pathfinder-10-on-the-cirrus-6000-and-the-cirrus-5000-100645379","NCT07680244","(CIRRUS-2023-1) CLINICAL CLIN Assessment of PathFinder 1.0 on the CIRRUS 6000 and the CIRRUS 5000","Inclusion Criteria:\n\n1. Able and willing to make the required study visits.\n2. Able and willing to give written informed consent and follow study instructions.\n3. Able and willing to complete ophthalmic imaging.\n4. Adults 18 years of age or older.\n\nThe subject population will be comprised of two groups (all categories below pertain to the central 6x6 mm macula area):\n\nGroup A\n\n1\\. Subjects with absence of macular abnormalities Group B\n\n1. Subjects with Disruption of the vitreoretinal interface (VRI)\n2. Subjects with Intraretinal hyporeflective space (IRHS)\n3. Subjects with Subretinal hyporeflective space (SRHS)\n4. Subjects with IS\u002FOS (Ellipsoid Zone) disruption\n5. Subjects with Retinal Pigment Epithelium (RPE) elevation\n6. Subjects with Retinal Pigment Epithelium (RPE) atrophy\n7. Other abnormalities\n\nExclusion Criteria:\n\n1. Inability to undergo the required tests.\n2. Unable to give consent or follow study instructions.\n3. Inability to fixate that precludes obtaining acceptable macula scans in the study eye.\n4. Visudyne (verteporfin) injection within the last 48 hours in the study eye.\n5. Pilocarpine or Vuity use within the last 24 hours in the study eye.\n6. Dense media opacity precluding adequate visualization of the retina in the study eye.\n7. Vitreous floaters that preclude obtaining acceptable scans in the study eye.",true,"18 Years",{"count":55,"type":20},400,[23],"This study will measure how well PathFinder 1.0 detects retinal abnormalities on macular cube OCT B-scans by assessing its sensitivity and specificity.",[59,60,61,62,63,64,65,66,67,68],"Epiretinal Membrane","Dry Age Related Macular Degeneration","Macular Abnormalities","Retina Disease","Vitreoretinal Abnormality","Intraretinal Hyporeflective Space","Subretinal Hyporeflective Space","IS\u002FOS (Ellipsoid Zone) Disruption","Retinal Pigment Epithelium (RPE) Elevation","Retinal Pigment Epithelium (RPE) Atrophy","RECRUITING","2026-06-29",{"date":72,"type":37},"2026-07-02",{"date":74,"type":37},"2025-05-23",{"date":76,"type":20},"2026-08",{"name":78,"class":44},"Carl Zeiss Meditec-Dublin CoCe",6,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":4,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":21,"phases":91,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":111},"100388585","phase-1-autologous-transplantation-of-induced-pluripotent-stem-cell-derived-retinal-pigment-epithelium-for-geographic-atrophy-associated-with-age-related-macular-degeneration-100388585","NCT04339764","Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","A Phase I\u002FIIa Trial for Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration","* INCLUSION CRITERIA:\n\nParticipant Eligibility Criteria:\n\nTo be eligible, the following inclusion criteria must be met, where applicable.\n\n* Participant must be 55 years of age or older.\n* Participant must have a diagnosis of dry AMD, defined as presence (or history, as documented in available color fundus photographs) of at least one medium or large druse (greater than or equal to 63 micrometer diameter) in the macula in at least one eye; AND presence of GA in at least one eye.\n* Participant must understand and sign the protocol s informed consent document.\n* Any participant of childbearing potential must have a negative pregnancy test at screening and must be willing to undergo pregnancy testing prior to RPE transplantation.\n* Any participant of childbearing potential and any participant able to father children who has a partner of childbearing potential must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse, or must agree to practice an effective method of contraception through Month 12 in the study. Acceptable methods of contraception include:\n\n  * Hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring),\n  * Intrauterine device,\n  * Barrier methods (diaphragm, condom) with spermicide, or\n  * Surgical sterilization (tubal ligation).\n* Participant must be medically able to comply with the study treatment (including ability to safely receive anesthesia for surgery), study testing and procedures, and follow-up visits.\n\nStudy Eye\u002FFellow Eye Eligibility Criteria\n\nThe participant must have at least one eye meeting all inclusion criteria and none of the exclusion criteria listed below. The fellow eye must also meet the relevant eligibility criteria listed below.\n\nStudy Eye Inclusion Criteria:\n\n* The study eye must have one or more regions of geographic atrophy with total area of 1 disc area or more. A region of geographic atrophy is defined as an area of uniform hypofluorescence on fundus autofluorescence (FAF) imaging, with greatest linear dimension at least 500 micrometer, with a border within 500 micrometer of the foveal center, not compatible with pigmentary changes, drusen, RPE detachment, drusenoid RPE detachment, hemorrhage, or other lesion. (Note: If macular geographic atrophy is contiguous with peripapillary atrophy, complicating calculation of total area, only atrophy temporal to a vertical line placed a half disc diameter temporal to the temporal border of the disc will be included in the total area of geographic atrophy calculated for eligibility purposes.)\n* For participants in the first cohort, the study eye must have an ETDRS best-corrected visual acuity (BCVA) letter score of \\\u003C= 53 and \\>= CF (i.e., Snellen equivalent between 20\u002F100 and CF), and the fellow eye must have a letter score no more than five letters worse than the study eye using Electronic Visual Acuity (EVA) testing. If the study eye is CF vision, then the fellow eye must be both (1) CF or better vision and (2) subjectively as good or better than the study eye according to the subject s perception. (Note: Letter scores within five or fewer letters of each other are accordingly considered equal for eligibility determination, and other factors may be used to select the study eye if both are eligible by BCVA.\n* For participants in the second cohort, the study eye must have an ETDRS best-corrected visual acuity (BCVA) letter score of \\\u003C= 58 and \\>= CF (i.e., Snellen equivalent between 20\u002F80 and CF), and the fellow eye must have a letter score no more than five letters worse than the study eye using Electronic Visual Acuity (EVA) testing. If the study eye is CF vision, then the fellow eye must be both (1) CF or better vision and (2) subjectively as good or better than the study eye according to the subject s perception. (Note: Letter scores within five or fewer letters of each other are accordingly considered equal for eligibility determination, and other factors may be used to select the study eye if both are eligible by BCVA.\n* The compromise in visual acuity for the study eye must be judged predominantly secondary to dry AMD, in the judgment of the investigator.\n* The study eye must have clarity of ocular media and degree of pupil dilation sufficient to permit adequate fundus photography and safe vitrectomy surgery.\n* The study eye must be either pseudophakic or aphakic.\n\nEXCLUSION CRITERIA:\n\nA participant is not eligible if any of the following exclusion criteria are present:\n\n* Participant is actively receiving another study medication \u002F investigational product (IP).\n* Participant has any condition that significantly increases risk of systemic corticosteroids or systemic steroid-sparing immuno-modulatory agents, such as uncontrolled diabetes mellitus (defined as HbA1C \\> 7.5 at Baseline), chronic hepatitis or liver failure (defined, as elevated liver function tests (LFTs): alanine transaminase (ALT) or aspartate transaminase (AST) \\>= 2x upper limit of normal at Baseline), kidney disease with an eGFR \\\u003C25 mL\u002Fmin\u002F1.73 m2 for 3 months or more or by any other evidence of disease chronicity, or present infection with HIV, syphilis, tuberculosis, hepatitis B, or hepatitis C (past infection now resolved, where applicable, is not exclusionary; but persistent infection, even if latent, is exclusionary).\n* Participant has diagnosis of a malignancy expected to affect two-year survival.\n* Participant is pregnant, breast-feeding, or planning to become pregnant through the first 12 months of the study.\n* Participant has a family history of a retinal degeneration other than AMD suspected to play a role in the ocular phenotype of the participant in the judgment of the investigator, based on disease features and mode of inheritance, such as in a case of autosomal dominant retinal degeneration in a parent or child.\n* Participant is taking, or has taken within the previous year, medication with known potential toxicity to the retina, optic nerve, or lens (such as chloroquine, hydroxychloroquine, ethambutol).\n* Participant is taking any form of systemic anticoagulation which cannot be stopped for an indefinite period of time without significant risk. The determination of significant risk to the participant must be at the discretion of the study investigators and prescribing physician (or qualified alternative).\n* Participant is unable or unwilling to give informed consent that includes use of medical records and clinical samples for current and future research.\n\nStudy Eye Exclusion Criteria:\n\n* The study eye has macular, subretinal or choroidal neovascularization, as assessed by FA and OCT; or any history of such neovascularization (as assessed by past available records or images).\n* The study eye has serous or hemorrhagic pigment epithelial detachment, as assessed by FA and OCT, that is clinically significant in the judgment of the investigator.\n* The study eye has a history of photodynamic therapy (PDT) or macular thermal laser photocoagulation, or history of intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents or corticosteroids (excepting medications used peri-operatively at prior cataract surgery). The study eye has had intravitreal injections (anti-complement therapy) for treatment of dry AMD in the previous 12 weeks before enrollment. Any intravitreal injections with anti-complement therapy prior to 12 weeks are not exclusionary.\n* The study eye has an axial length \\> 25.0 mm.\n* The study eye has had surgery in the previous 12 weeks, or laser capsulotomy in the previous four weeks.\n* The study eye has chronic glaucoma; OR significant ocular hypertension, defined as documented intraocular pressure of \\>= 26 mmHg on at least two occasions in the absence of self-limited acute glaucoma; OR history of probable or definite steroid response manifesting as acute glaucoma or ocular hypertension, even if self-limited and no longer present; OR the fellow eye has evidence for present or past glaucoma or ocular hypertension judged to significantly impact the risk of glaucoma in the study eye (including history of probable or definite steroid response). (Note: History of self-limited acute glaucoma in a study or fellow eye, if not secondary to steroid response, and if now resolved and not expected to recur (e.g., history of elevated intraocular pressure from retained visco-elastic after cataract surgery), is not exclusionary. History of glaucoma or ocular hypertension in the fellow eye, if not felt to significantly impact risk of glaucoma in the study eye, is not exclusionary.)\n* The study eye has a condition materially increasing the risks of surgery or potentially affecting visual function over the next two years in the judgment of the investigator, such as chronic uveitis, diabetic retinopathy, keratitis, scleritis, optic neuropathy, untreated retinal detachment, macular edema from prior vein occlusion or other cause, proliferative vitreoretinopathy (PVR), vitreous hemorrhage, pathologic myopia, etc. A history of such conditions is not exclusionary, if judged to not materially increase risks of surgery or to potentially affect vision in the next two years in the opinion of the investigator.","55 Years","95 Years",{"count":90,"type":20},20,[92,93],"PHASE1","PHASE2","Background:\n\nAge-related macular degeneration is a common eye disease in people over 50. The \"dry\" form of the disease can worsen into geographic atrophy, causing blind spots. Researchers want to learn if replacing older eye cells with younger ones can help treat this disease.\n\nObjective:\n\nTo test the safety of putting cells inside the eye as a possible future treatment for dry age-related macular degeneration.\n\nEligibility:\n\nPeople ages 55 and older who have geographic atrophy with loss of vision. People who have had \"wet\" macular degeneration in study eye are NOT eligible.\n\nDesign:\n\nParticipants will be screened with:\n\n* Medical history\n* Physical exam\n* Blood and urine tests\n* Eye exam\n* Eye photos\n* Fluorescein angiography. An intravenous (IV) line is placed in an arm vein. A dye is injected. A camera takes pictures of the dye as it flows through the eyes' blood vessels.\n* Electroretinography. An electrode is taped to participants' forehead. They sit in the dark. After 30 minutes, numbing eye drops and contact lenses are placed in their eyes. They watch flashing lights.\n* Tuberculosis test\n* Chest X-ray\n* Electrocardiography. Sticky pads are placed on participants' chest to record the heart's electrical activity.\n\nParticipants will have at least 14 study visits over 5 and a half years. They will repeat screening tests.\n\nParticipants will have retinal pigment epithelium (RPE) transplantation surgery in one eye. For this, cells from participants' blood are turned into RPE cells. These cells are placed in their eye through a cut in their retina. They will get dilating eye drops, an IV line, and anesthesia that may make them sleep. A gas bubble will be put in their eye to help it heal. Participants will receive immunosuppressive medications to avoid transplant rejection.\n\nParticipants will be contacted yearly for up to 15 years.",[26,96],"Geographic Atrophy",[98,99,100],"Retina","Cell Therapy","Vitrectomy","2026-06-23",{"date":103,"type":37},"2026-06-24",{"date":105,"type":37},"2020-09-23",{"date":107,"type":20},"2029-05-31",{"name":109,"class":110},"National Eye Institute (NEI)","NIH",2,{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":21,"phases":123,"briefSummary":124,"conditions":125,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":136},"100558925","phase-2-a-phase-iib-randomized-multicenter-trial-of-subretinal-cpcb-rpe1-in-advanced-dry-amd-geographic-atrophy-100558925","NCT06557460","A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)","A Phase IIb, Randomized, Assessor-Masked, Multicenter Clinical Trial to Assess the Safety and Efficacy of Subretinal Implantation of the CPCB-RPE1 Implant in Subjects With Advanced, Dry Age-Related Macular Degeneration (Geographic Atrophy) - PATCH AMD","PATCH-AMD","Eligible participants include:\n\n1. Age 55 to 90 years of age (inclusive), presenting with geographic atrophy involving the fovea in advanced, age-related, dry AMD.\n2. Clinical findings consistent with advanced dry AMD with evidence of one or more areas of ≥4.0mm2 but not exceeding 15.0 mm2 of geographic atrophy involving the fovea.\n3. Geographic atrophy defined as attenuation or loss of RPE as observed by biomicroscopy, OCT, or FAF.\n4. The best-corrected visual acuity (BCVA) of the eye to receive the implant will be ≥20\u002F200 (35 EDTRS letters) to 20\u002F63 (60 EDTRS letters) inclusive. The BCVA of the eye that is NOT to receive the implant will be better or equal to the eye that will receive the implant.\n5. Medically suitable to undergo pars plana vitrectomy and the surgical implant procedure, including being able to position post-operatively and use post-operative medications as required.\n6. Medically suitable for general anesthesia or monitored intravenous sedation, if needed.\n7. Pseudophakic in the study eye, to remove the risk of cataract formation following vitrectomy.\n8. Participants also must be willing and able to provide written, signed informed consent for this study.\n9. Participants able to complete the baseline microperimetry retinal sensitivity testing.\n10. On baseline microperimetry, participants must have ≥5 spots in the perilesional region with a retinal sensitivity between 3 and 17 Db.","90 Years",{"count":122,"type":20},24,[93],"This is a Phase IIb randomized, clinical trial designed to assess the safety and efficacy of unilateral implantation of the CPCB-RPE1 implant in subjects with geographic atrophy involving the fovea.\n\nUp to 6 surgical implantation sites will deliver the CPCB-RPE1 in this Phase IIb clinical trial. Additional study sites may serve as referral or follow-up sites. Twenty-four (24) subjects will participate in the trial and will be randomized 3:1 to one of 2 groups:\n\n* The treatment group receiving the CPCB-RPE1 implant (up to 18 subjects).\n* The control group receiving a simulated \"sham\" implantation procedure (up to 6 subjects)",[126,96],"Dry Age-related Macular Degeneration","2026-03-22",{"date":129,"type":37},"2026-03-25",{"date":131,"type":37},"2025-08-01",{"date":133,"type":20},"2040-12",{"name":135,"class":44},"Regenerative Patch Technologies, LLC",5,{"id":138,"slug":139,"hasResults":11,"nctId":140,"briefTitle":141,"officialTitle":142,"acronym":4,"eligibilityCriteria":143,"healthyVolunteers":11,"sex":16,"minAge":87,"maxAge":4,"enrollmentInfo":144,"targetDuration":4,"studyType":21,"phases":146,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":45},"100410662","phase-1-safety-and-tolerability-of-rpe-stem-cell-derived-rperpesc-rpe-transplantation-in-patients-with-dry-age-related-macular-degeneration-amd-100410662","NCT04627428","Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)","A Phase1\u002F2a, Open-Label Study to Evaluate the Safety and Tolerability of RPE Stem Cell-derived RPE (RPESC-RPE) Transplantation as Therapy for Dry Age-related Macular Degeneration (AMD)","Inclusion Criteria:\n\n1. Clinical diagnosis of dry AMD.\n2. Ability to understand and give informed consent.\n3. Adult male or female \\>55 years of age.\n4. Medically suitable to undergo vitrectomy and subretinal injection (\\>60% on Karnofsky scale).\n5. Postmenopausal if female (expected to be common for the age limitation), or the female partner of a male subject unable to father children.\n6. If male, willing to use barrier and spermicidal contraception during the study.\n\nExclusion Criteria:\n\n1. Allergy or hypersensitivity to dilation drops or fluorescein.\n2. Active major medical conditions limiting ability to participate in the study.\n3. Active malignancy or treatment with chemotherapy.\n4. Systemic immunosuppressant therapy within past six months.\n5. History of toxoplasmosis, retinal histoplasmosis or tuberculosis.\n6. Receipt of investigational product (IP) in a clinical trial within prior six months.\n7. Any other medical condition, which, in the Investigator's judgment, will interfere with the subject's ability to comply with the protocol, compromises subject safety, or interferes with the interpretation of the study results.\n8. Pregnant or nursing females.",{"count":145,"type":20},18,[92,93],"The main objective of the study is evaluation of the safety and tolerability of RPESC-RPE-4W as therapy for dry AMD.",[126],"2025-10-12",{"date":151,"type":37},"2025-10-15",{"date":153,"type":37},"2022-04-05",{"date":155,"type":20},"2026-12-01",{"name":157,"class":44},"Luxa Biotechnology, LLC",{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":21,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":172,"lastUpdatePostDateStruct":173,"startDateStruct":175,"completionDateStruct":177,"leadSponsor":179,"locationsCount":182},"100493572","atrophic-age-related-macular-degeneration-treated-with-intravitreal-injections-of-umbilical-cord-blood-platelet-rich-plasma-100493572","NCT05706896","Atrophic Age-related Macular Degeneration Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma","Atrophic Age-related Macular Degeneration (AMD) Treated With Intravitreal Injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP): a Pilot Study","CORD-IV","Inclusion Criteria:\n\n* Age ≥65 years\n* Bilateral dry-AMD\n* ETDRS-corrected visual acuity between (or equal to) 1\u002F10 and 4\u002F10\n* No concomitant ocular pathology (e.g., Glaucoma, amblyopia) or systemic pathology that would result in a BIAS for primary goal assessment\n* Signature of informed consent\n\nExclusion Criteria:\n\n* Age \\\u003C 65 years\n* Pregnancy\n* Previous inflammatory\u002Finfectious events involving the eyes\n* Eye trauma, diabetes, or disease potentially damaging to the visual system, even in the absence of impairment at the time of intake\n* Previous intravitreal treatments.\n* Refusal to sign informed consent.","65 Years",{"count":168,"type":20},36,[23],"The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD)",[126],"2025-09-18",{"date":174,"type":37},"2025-09-23",{"date":176,"type":37},"2022-12-14",{"date":178,"type":20},"2026-02-10",{"name":180,"class":181},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",1,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":16,"minAge":166,"maxAge":4,"enrollmentInfo":190,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":182},"100557280","age-related-macular-degeneration-of-atrophic-type-treated-with-umbilical-cord-blood-enriched-with-platelet-plasma-100557280","NCT06536062","Age-related Macular Degeneration of Atrophic Type Treated With Umbilical Cord Blood Enriched With Platelet Plasma.","Age-related Macular Degeneration of Atrophic Type Treated With Intravitreal Injection of Umbilical Cord Blood Enriched With Platelet Plasma: Multicenter Study.","M-CORD IV",{"count":168,"type":20},[23],"The objective of the study will be to evaluate the efficacy of intravitreal injections of Umbilical Cord Blood Platelet-rich Plasma (CB-PRP) in order to reduce or stabilize the atrophic progression in dry Age-related Macular Degeneration (AMD).",[126],"2025-09-17",{"date":174,"type":37},{"date":197,"type":37},"2024-07-20",{"date":199,"type":20},"2026-07-30",{"name":180,"class":181},{"id":202,"slug":4,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":207,"targetDuration":4,"studyType":21,"phases":209,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":111},"100594844","NCT07024732","A Safety and Tolerability Clinical Trial of PST-611 in Dry Age-related Macular Degeneration","An Open-label Single Ascending Dose Safety and Tolerability Clinical Trial of PST-611 in Subjects With Dry Age-related Macular Degeneration","Inclusion Criteria:\n\nSubjects must give written informed consent, be able to make the required trial visits and follow instructions.\n\nFemale and male subjects must be 50 years of age or older. Female subjects of childbearing potential must not be pregnant or breast-feeding and must have a negative urine pregnancy test at baseline and throughout the study. They must agree to practice at least one effective method of birth control following administration of study medication.\n\nIn the study eye, at least one of the following must be present at OCT and attributed to AMD, as evaluated by the Investigator: Incomplete RPE and Outer Retinal Atrophy (iRORA), or Complete RPE and Outer Retinal Atrophy (cRORA).\n\nBest-Corrected Visual Acuity (BCVA), must be 23 ETDRS letters (approximate Snellen equivalent 20\u002F320) or better in the study eye.\n\nSubject's fellow eye BCVA must be 34 letters (approximate Snellen equivalent 20\u002F200) or better.\n\nExclusion Criteria:\n\nBoth eyes: any active intraocular or periocular infection or inflammation (eg, infectious blepharitis, infectious conjunctivitis, keratitis, scleritis, endophthalmitis), or history of intraocular or periocular infection or inflammation in the 12 weeks (84 days) prior to the PST-611 administration.\n\nStudy eye: Any intraocular surgery (including cataract surgery) or intravitreal (IVT) or periocular corticosteroid injection within 12 weeks (84 days) prior to the PST-611 administration.\n\nStudy eye: Any anti-VEGF IVT treatment within 4 weeks (28 days) prior to PST-611 dosing OR subjects who have required and received regular monthly injections of anti-VEGF drugs in the months preceding the trial and would thus have a higher likelihood of requiring and anti-VEGF treatment within 28 days of the PST-611 administration.\n\nStudy eye: media opacity that interferes with fundus imaging or is likely to require surgery during the trial period.\n\nStudy eye: subject with history of glaucoma filtering surgery (e.g. trabeculectomy or aqueous shunt implant) or who underwent eye surgery within 12 weeks (84 days) of the PST-611 administration. Study eye: subject who has uncontrolled intraocular pressure of ≥ 25 mmHg in the SE at the screening and baseline visits.",{"count":208,"type":20},12,[92],"The goal of this interventional study is to evaluate the safety and tolerability of single ascending doses of PST-611 in men and women over the age of 50 with dry age-related macular degeneration (AMD).\n\nThe main question it aims to answer is: Is PST-611-CT1 safe for participants?\n\nParticipants will:\n\n* Receive a single dose of PST-611\n* Will be followed up for a total of 16 weeks following PST-611 administration",[60],[60,213],"PST-611","2025-06-09",{"date":216,"type":37},"2025-06-17",{"date":218,"type":20},"2025-07",{"date":220,"type":20},"2026-06",{"name":222,"class":44},"Eyevensys",{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":52,"sex":16,"minAge":87,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":234,"phases":4,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":4},"100583156","study-to-detect-dendritic-cell-recruitment-in-human-retina-100583156","NCT06872658","Study to Detect Dendritic Cell Recruitment in Human Retina","Exploratory Open-Label Study for the Development of a Method to Detect Dendritic Cell Recruitment in the Human Retina at Sites of Inflammatory Disease and Complement System Activation","ICG-002","Inclusion Criteria:\n\n1. All Study Participants\n\n   * Male or female and between the ages of 55 to 80 years old (inclusive)\n   * Participants are determined by the qualified investigator to be medically stable and able to understand and agree to comply with the study procedures and report for scheduled study visits.\n   * Participants have adequate hearing, vision, and language skills to provide informed consent and to cooperate with all retinal imaging, cognitive testing, interviews and other medical procedures as specified in the protocol. Hearing augmentation (i.e., hearing aids) are allowed.\n   * Participants are able to reliably communicate with study personnel about adverse events (AEs) and concomitant medications.\n   * Provide signed written informed consent according to institutional guidelines. Participants with mild AD must be able to provide assent and be accompanied by a relative or caregiver who is empowered to provide written consent.\n   * Permitted medications stable for at least 1 month prior to screening. In particular:\n\n     * Participants may take stable doses of antidepressants lacking significant anticholinergic side effects (if they are not currently depressed and do not have a history of major depression within the past year).\n2. Healthy Elderly Participants\n\n   * MMSE score \\> 27\n   * CDR score = 0\n   * No current or past history of first-degree relative(s) with either a diagnosis of AD or suspected AD, and no subjective memory impairment with persisting worries.\n   * If any such test results are available, no APOE e4 allele positivity or abnormal beta-amyloid protein aggregation as assessed by blood plasma, PET imaging or CSF analyses.\n   * No evidence of any retinal\u002Focular diseases, other than myopia or hyperopia\n   * No evidence of any neurological \u002F neurodegenerative diseases\n3. Participants with Dry AMD with GA\n\n   * MMSE score \\> 27\n   * CDR score = 0\n   * Advanced non-neovascular stage AMD, as determined by qualified neuro-ophthalmologist or retinal specialist\n   * No evidence of choroidal neovascularization (CNV) in study eye - current or historical\n   * Best Corrected Visual Acuity (BCVA) ≥ 20\u002F80\n   * Low-luminance visual acuity deficit, defined as the difference between BCVA and LLVA \\> 5 letters\n   * Cumulative GA lesion size 1.27 mm2 (approximately ≥ 0.5 disc area (DA)) and ≤ 10.16 mm2 (approximately ≤ 4.0 DA). Standard DA is equivalent to 2.54 mm2 on the retina.\n   * Participants with Dry AMD who are not (yet) being treated with a complement system inhibitor (intravitreal injections).\n4. Participants with Mild Cognitive Impairment (MCI) due to AD or mild AD\n\n   * MMSE score \\> 21\n   * CDR score between 0.5 and 1.0\n   * MoCA total score \\> 18 and \\\u003C 26 at screening\n   * Positive prior biomarker evidence of Alzheimer's disease (blood plasma marker(s), PET imaging, or CSF assays), by review of available medical records\n   * A clinical diagnosis of either mild cognitive impairment (MCI) due to AD, or mild AD, from qualified specialist or from a memory disorders clinic or center\n   * Participants must have a study partner (i.e., family member, close friend, or caregiver) who can attend study appointments with them.\n   * Because this study does not include any form of therapeutic intervention, participants' concurrent enrollment in other clinical trials for MCI or AD is allowed, including those that involved the use of investigational drugs. Relevant information about other studies in which individuals are participating (e.g., study name, sponsor) will be made available and recorded on their case report forms (CRFs).\n\nExclusion Criteria:\n\n1. Medical History\n\n   * Participants with a history of any anaphylactic reactions to drugs\n   * Participants with a history of allergic reaction to ICG\n   * Participants with a history of iodine sensitivity and\u002For allergic reaction to iodine\n   * Participants with a history of a clinically significant hepatic disease\n   * Participants with a Modified Hachinski Ischemia Scale (MHIS) score \\> 2\n   * Participants with a known hypersensitivity to tropicamide eye drops or other anticholinergic medications\n2. Participants with histories of other ocular or neurologic disease that could affect the results including, but not limited to, diabetic retinopathy or glaucoma.\n3. Geriatric Depression Scale Short Form (GDS-S 15 Items) score \\> 6.\n4. Target Disease Exceptions\n\n   * Any participant diagnosed to have an autoimmune disorder, including but not limited to\n\n     * Psoriasis\n     * Lupus\n     * Rheumatoid arthritis\n     * Crohn's disease\n     * Multiple sclerosis\n     * Alopecia areata\n   * Any participant who has any unstable cardiovascular (included uncontrolled hypertension), pulmonary, or GI disease.\n   * History of alcohol or substance abuse and\u002For dependence within the past 2 years (DSM-V criteria).\n   * History of schizophrenia or a history of psychotic features, agitation or behavioral problems within the last 3 months, which could lead to difficulty complying with the protocol.\n   * Participants who, in the investigator's opinion, will not comply with study procedures.\n   * Participants who, in the investigator's opinion, have any significant systemic illness or unstable medical condition which could lead to difficulty complying with the protocol including (but not limited to):\n\n     * History of myocardial infarction within the past six (6) months or unstable or severe cardiovascular disease including angina or CHF with symptoms at rest.\n     * Uncontrolled hypertension (i.e., systolic BP \\> 170 or diastolic BP \\> 100)\n     * Uncontrolled (A1C\\>7) or insulin requiring diabetes.\n     * History of symptoms of narrow-angle glaucoma (warning signs include eye pain, restricted vision, blurred vision)\n     * History of elevated intraocular pressure, or medical record evidence of intraocular pressure \\> 20 mm Hg\n5. Concurrent Medications\n\n   * Any participant who is immunocompromised at screening including taking medications that are systemic immunosuppressives including corticosteroids but not NSAIDS\n   * Any participant currently prescribed a biologic immunosuppressive therapy or having taken such therapy in the prior 3 months, including\n\n     * abatacept (Orencia)\n     * adalimumab (Humira)\n     * anakinra (Kineret)\n     * certolizumab (Cimzia)\n     * etanercept (Enbrel)\n     * golimumab (Simponi)\n     * infliximab (Remicade)\n     * ixekizumab (Taltz)\n     * natalizumab (Tysabri)\n     * rituximab (Rituxan)\n     * secukinumab (Cosentyx)\n     * tocilizumab (Actemra)\n     * ustekinumab (Stelara)\n     * vedolizumab (Entyvio)\n     * Monoclonal antibodies\n     * basiliximab (Simulect)\n     * daclizumab (Zinbryta)\n   * Regular (daily) use of narcotics or antipsychotic medications. Low doses for off-label use may be permitted, as determined by the principal investigator's clinical judgment and if stable for 4 weeks prior to screening.\n   * New use of anti-Parkinsonian medications (e.g., sinemet, amantaine, bromocriptine, pergolide and selegiline) within 2 months prior to screening. Low doses for off-label use may be permitted, as determined by the principal investigator's clinical judgment and if stable for 2 months prior to screening.\n   * New use of anti-convulsants (e.g., phenytoin, phenobarbital, carbamazepine) within 2 months prior to screening. Low doses for off-label use may be permitted, as determined by the principal investigator's clinical judgment and if stable for 2 months prior to screening.\n   * New use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4 weeks prior to screening.\n   * New use of neuroleptics or narcotic analgesics within 4 weeks prior to screening.\n   * New and chronic use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screening.\n   * Initiation or change in dose of an antidepressant within 4 weeks prior to screening (use of stable doses of antidepressants for at least 4 weeks prior to screening is acceptable)\n   * Any participant currently or previously treated for Dry AMD with a complement system inhibitor.\n6. Physical and Laboratory Test Findings at Screening\n\n   * Any participant, in the clinical judgement of the qualified investigator, with uncontrolled hypertension, abnormal systolic BP, or abnormal heart rate at screening (e.g., repeated diastolic measurements ≥ 96 mmHg).\n   * Any participant with either of the following hepatic test abnormalities at screening:\n\n     * Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \\> 2.0 times the institutional ULN\n     * Total Bilirubin \\> 2 times the institutional ULN\n   * Any participant with P-Amylase or Lipase values \\> 2 times the ULN at screening\n   * Any participant at screening with insulin-dependent diabetes mellitus or HbA1C ≥ 6.5%\n   * Abnormal liver function test laboratory results, as determined by screening visit (pre-ICG infusion) safety lab tests\n   * Any participant at screening with pathologic renal findings as defined by the presence of calculated glomerular filtration rate (GFR) (creatinine clearance) ≤45 ml\u002Fmin\u002F1.73m2 (2021 revision of CKD-EPI formula for GFR estimate)\n   * Any participant at screening with any of the following hematologic abnormalities:\n\n     * Hemoglobin \\\u003C 10g\u002FdL\n     * WBC \\\u003C 3.0 x 103\u002Fmm3\n     * Platelet count \\\u003C 100,000\u002Fmm3\n   * Any participant who has a known infection with a human immunodeficiency virus, hepatitis B virus, or hepatitis C virus.\n   * Any participant with a positive urine drug screen with no concomitant medication to justify the results.","80 Years",{"count":233,"type":20},15,"OBSERVATIONAL","The goal of this study is to develop an optimal method to detect the immune cells (cells that protect the human body against diseases) in association with abnormal conditions of the retina (light sensitive tissue in the back of the eye) that will be relevant to diseases such as age related macular degeneration (AMD), mild cognitive impairment (MCI) due to Alzheimer's Disease (AD) or mild AD.\n\nThe main objectives of this study are:\n\n1. Establish Optimal Method for Retinal Imaging of Dendritic Cells (DCs)\n2. Safety and Tolerability of ICG infusion in normal healthy, older adult volunteers, in participants with AMD (Dry AMD with Geographic Atrophy (GA)), and in participants who have received a diagnosis of either Mild Cognitive Impairment (MCI) due to AD, or mild AD",[60,237,238],"Mild Cognitive Impairment (MCI)","Alzheimer Disease",[27,60,240,241,242,238],"AD","MCI","Mild Cognitive Impairment","2025-03-06",{"date":245,"type":37},"2025-03-12",{"date":247,"type":20},"2025-05-01",{"date":249,"type":20},"2026-01-01",{"name":251,"class":44},"MindImmune Therapeutics, Inc.",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":259,"targetDuration":261,"studyType":234,"phases":4,"briefSummary":262,"conditions":263,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":264,"lastUpdatePostDateStruct":265,"startDateStruct":267,"completionDateStruct":269,"leadSponsor":271,"locationsCount":182},"100543110","a-registry-study-to-assess-photobiomodulation-in-dry-age-related-macular-degeneration-eurolight-eurolight-100543110","NCT06351605","A Registry Study to Assess Photobiomodulation in Dry Age-Related Macular Degeneration (EUROLIGHT) (EUROLIGHT)","A Multi-Center Registry Study to Assess the Safety and Effectiveness of Photobiomodulation in Participants With Dry Age-Related Macular Degeneration (EUROLIGHT)","Inclusion Criteria:\n\n1. Diagnosis or confirmation of diagnosis of dry AMD disease by Investigator\n2. Able to communicate well with the Investigator and able to understand and comply with the requirements of the study\n3. Informed of the nature of this study and has provided written, informed consent (participants enrolled retrospectively will need to be contacted and sign an informed consent form prior to their data being used).\n\nExclusion Criteria:\n\n1. Signs of active, inactive or history of exudative macular neovascularization (MNV)\n2. History or active accumulation of intra and subretinal fluid of any cause (e.g., diabetic macular oedema, central serous retinopathy, cystoid macular oedema)\n3. Use of any photosensitizing agent (e.g. topicals, injectables) activated by the Valeda Light Deliver System within 30 days prior to treatment without consulting participant's physician\n4. Has any known photosensitivity to yellow light, red light, or near infrared radiation (NIR), or has a history of light activated CNS disorders (e.g. epilepsy, migraine)\n5. In the opinion of the Investigator, is unlikely to comply with the study protocol or has a history or current evidence of any condition that, in the opinion of the investigator, might interfere with the participant's involvement in the trial, or is not in the best interest of the participant.",{"count":260,"type":20},500,"3 Years","The EUROLIGHT study is being conducted to collect real life data for the safety and effectiveness of PBM in dry AMD, in routine clinical practice both retrospectively and prospectively.",[126],"2024-04-02",{"date":266,"type":37},"2024-04-08",{"date":268,"type":37},"2023-09-01",{"date":270,"type":20},"2026-12",{"name":272,"class":44},"LumiThera, Inc.",{"id":274,"slug":275,"hasResults":11,"nctId":276,"briefTitle":277,"officialTitle":277,"acronym":4,"eligibilityCriteria":278,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":280,"targetDuration":4,"studyType":21,"phases":282,"briefSummary":284,"conditions":285,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":182},"100528768","phase-3-effects-of-antiplatelet-and-antioxidant-agents-on-drusen-progression-a-pilot-prospective-cohort-study-100528768","NCT06165068","Effects of Antiplatelet and Antioxidant Agents on Drusen Progression: A Pilot, Prospective Cohort Study","Inclusion Criteria:\n\n* Dry AMD with at least 1 large drusen. According to the AREDS study, large drusen have a size of more than 125 micron.\n* Patients can evaluate SD-OCT (Spectral domain optical coherence tomography), OCT angiography, and best-corrected visual acuity.\n* Age range: 50-85 years\n* Patients who have previously used antiplatelet drugs.\n\nExclusion Criteria:\n\n* Patient with advanced AMD, such as geographic atrophy, neovascular complications (choroidal neovascularization)\n* Patient with additional retinal diseases that affect visual acuity, e.g., retinal detachment, diabetic macular edema.\n* Patient with a history of intravitreal anti-VEGF injection or macular laser.\n* Patient using SSRIs, SNRIs, azole, NSAIDs, dual antiplatelet, anticoagulant medications.","85 Years",{"count":281,"type":20},174,[283],"PHASE3","The aim of this clinical trial is to evaluate the effect of low doses of antiplatelet medications (aspirin 81 mg\u002Fday or clopidogrel 75 mg\u002Fday) with or without a combination of antioxidants (N-acetylcysteine 600 mg\u002Fday) in a dry AMD patient with large drusen.\n\nParticipants will divided in to three groups.\n\n* Participants who were already taking low dose antiplatelet medications.\n* Participants who take the antiplatelet drug mentioned above in addition to the antioxidant prescribed by the investigator\n* Participants does not use any medications.",[126],"2023-12-11",{"date":288,"type":37},"2023-12-15",{"date":290,"type":20},"2023-12",{"date":292,"type":20},"2026-09",{"name":294,"class":181},"Navamindradhiraj University",{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":4,"eligibilityCriteria":301,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":302,"enrollmentInfo":303,"targetDuration":4,"studyType":234,"phases":4,"briefSummary":304,"conditions":305,"keywords":307,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":309,"lastUpdatePostDateStruct":310,"startDateStruct":312,"completionDateStruct":314,"leadSponsor":315,"locationsCount":4},"100429681","vision-improvement-for-legally-blind-dry-amd-patients-100429681","NCT04875234","Vision Improvement for Legally Blind Dry AMD Patients","Vision Improvement for Legally Blind Dry Age-Related Macular Degeneration Patients","IInclusion Criteria:\n\n* Male or Female\n* Any race\n* Patient is at least 50 years old.\n* Patient must have dry AMD in the study eye.\n* Patient is legally blind due to AMD - i.e., has corrected distance visual acuity (CDVA) of 20\u002F125 or worse (45 letters; logMAR ≥ 0.80) in the study eye.\n* Patient has normal corneal surface topography on videokeratography (i.e., without distorted or unclear corneal mires).\n* Patient is not a contact lens wearer.\n* Patient is willing and able to comply with all examinations.\n* Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria:\n\n* Visually significant cataract in the study eye\n* Presence of a visually significant posterior capsule opacity if prior cataract surgery has been performed in the study eye\n* Any visually significant disease process in any ocular structure other than AMD that would affect vision in the study eye\n* Previous corneal surgery in the study eye\n* Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or may confound the outcome of the study","100 Years",{"count":19,"type":20},"This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.",[126,306],"Vision Impairment and Blindness",[308],"AMD, vision impairment, blindness","2023-03-21",{"date":311,"type":37},"2023-03-22",{"date":313,"type":20},"2024-01",{"date":270,"type":20},{"name":316,"class":44},"Optimal Acuity Corporation",{"id":318,"slug":319,"hasResults":11,"nctId":320,"briefTitle":321,"officialTitle":322,"acronym":4,"eligibilityCriteria":323,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":279,"enrollmentInfo":324,"targetDuration":4,"studyType":234,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":328,"lastUpdatePostDateStruct":329,"startDateStruct":331,"completionDateStruct":333,"leadSponsor":335,"locationsCount":182},"100471388","observation-of-the-natural-course-of-age-related-macular-degeneration-100471388","NCT05418231","Observation of the Natural Course of Age-related Macular Degeneration","Observation of the Natural Course of Dry Age-related Macular Degeneration","Inclusion Criteria:\n\n* 50-85 yrs male or female AMD patients\n* Dry-AMD patients in either early, intermediate, or intermediate-to-late stage confirmed by fundus examinations.\n\nExclusion Criteria:\n\n* Any eye with disease that would interfere with the retinal examinations\n* Research eye with CNV or high myopia\n* Surgeries that may interfere with AMD evaluation\n* Long-term uses of medications that are associated with retinal or neural toxicities.\n* IOP more than 26 mmHg\n* Received cataract surgery in 3 months.\n* Other conditions: diseases that causes less than 5 years survival; any condition that causes high risk of drop-out, or low compliance, for instance cognition disorder; have been involved in other trial that interfere with the current visit plan; taking other angiogenesis Inhibitors drugs for treating cancer.\n* Other conditions not suitable for the current study",{"count":260,"type":20},"This research will study natural course of dry AMD in Chinese population, screen fundus imaging indicators for patients with Chinese dry AMD, describe the clinical features of Chinese patients with dry AMD, and obtain a biological sample library of dry AMD mainly in China.",[126,327],"Macular Degeneration, Dry","2022-06-09",{"date":330,"type":37},"2022-06-14",{"date":332,"type":20},"2022-07",{"date":334,"type":20},"2027-07",{"name":336,"class":181},"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine"]